Professor Martin Birchall, Chair of Laryngology at the UCL Ear Institute, is leading on a new clinical trial looking at the use of stem cell-based tissue engineered laryngeal implants for certain airway disorders.
The Phase 1/2 clinical trial, entitled RegenVOX, is funded by the Medical Research Council. It involves a number of Martin's colleagues from across UCL and beyond, including:
- Professor Anne GM Schilder
- Dr Mark Lowdell
- Dr Sam Janes
- Professor Chris Mason
- Mr Guri Sandu
- Dr Tahera Ansari (Northwick Park Institute for Medical Research)
- Professor Anthony Hollander (University of Liverpool).
The trial is being sponsored by UCL and co-ordinated by the Comprehensive Clinical Trials Unit. It will be looking at the safety and efficacy of using laryngeal implants to treat patients with severe irreversible structural disorders of the larynx who are unresponsive to conventional treatment.
Further information about the clinical trial is available via the US NIH Clinical Trials Registry website (link below)
If you would like to receive more information about the trial's Patient and Public Involvement (PPI) group, please contact Fatima Zaman at the UCL Clinical Trials Unit.